Evofem Biosciences, Inc. (EVFM) Stock Analysis

Evofem Biosciences, Inc. (EVFM) Healthcare & Pipeline Overview

Evofem Biosciences, Inc. develops and commercializes products for women's sexual and reproductive health, primarily Phexxi, a non-hormonal contraceptive vaginal gel. The company operates in the competitive biotechnology sector, addressing unmet needs in women's health with a focus on innovative solutions.

What Is the Investment Thesis for EVFM?

Evofem Biosciences, Inc. presents a focused investment opportunity within the women's health sector. The primary value driver is the continued adoption and market penetration of Phexxi, the company's non-hormonal contraceptive gel, which caters to a specific segment of women seeking hormone-free options. Growth catalysts include successful clinical trials for EVO100, potentially expanding the product line to address sexually transmitted infections. The company's gross margin of 74.7% indicates strong pricing power. However, potential risks include competition from established contraceptive methods and the challenges of marketing a novel product in a competitive landscape. The company's future success hinges on its ability to effectively commercialize Phexxi and advance its pipeline of product candidates.

Based on FMP financials and quantitative analysis

EVFM Key Highlights

Phexxi is the company's commercial product, a non-hormonal vaginal gel for contraception.

• EVO100 is an antimicrobial vaginal gel in development for preventing urogenital transmission of Chlamydia trachomatis and Neisseria gonorrhoeae infections.
• The company's profit margin is 1.9%.
• Gross margin stands at 74.7%, indicating strong pricing power.
• Beta is -1.29, suggesting the stock is less volatile than the market.

Who Are EVFM's Competitors?

EVFM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are EVFM's Key Strengths?

Unique product offering (non-hormonal contraceptive).

• Proprietary technology and patents.
• Focus on unmet needs in women's health.

What Are EVFM's Weaknesses?

Limited product portfolio.

• Reliance on a single commercial product (Phexxi).
• Small company size and limited resources.

What Could Drive EVFM Stock Higher?

EVFM catalyst: Clinical trial results for EVO100, potentially expanding the product line to address sexually transmitted infections.

• Continued marketing and sales efforts to increase adoption of Phexxi.
• Potential partnerships with healthcare providers and distributors to expand market reach.

What Are the Key Risks for EVFM?

Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.

• Competition from established contraceptive methods and other women's health products.
• Regulatory hurdles and delays in the development and approval of new products.
• Reliance on a single commercial product (Phexxi) and the need to diversify revenue streams.
• Financial risks associated with operating in the biotechnology industry, including the need to raise capital to fund research and development.

What Are the Growth Opportunities for EVFM?

• Expansion of Phexxi Market Share: Phexxi's non-hormonal formulation caters to a specific segment of the contraceptive market seeking alternatives to traditional hormonal methods. The addressable market includes women who are hesitant to use hormones or experience adverse side effects. Evofem can increase market share through targeted marketing campaigns, partnerships with healthcare providers, and direct-to-consumer advertising. Success in capturing a larger share of the contraceptive market would drive revenue growth and establish Phexxi as a leading non-hormonal option.
• Successful Development and Commercialization of EVO100: EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis and Neisseria gonorrhoeae infections, represents a significant growth opportunity for Evofem. The market for STI prevention is substantial, driven by the increasing prevalence of these infections. Successful clinical trials and regulatory approval of EVO100 would allow Evofem to expand its product portfolio and address a broader range of women's health needs. The timeline for EVO100's development and commercialization depends on the progress of clinical trials and regulatory review.
• Geographic Expansion: Currently, Evofem's primary market is the United States. Expanding into international markets represents a significant growth opportunity. The demand for women's health products is global, and Evofem could leverage its existing product portfolio and expertise to enter new markets. International expansion would require regulatory approvals, distribution agreements, and localized marketing strategies. The timeline for geographic expansion depends on the specific markets targeted and the regulatory landscape in those regions.
• Strategic Partnerships and Acquisitions: Evofem can pursue strategic partnerships and acquisitions to expand its product portfolio, access new technologies, and strengthen its market position. Collaborations with other companies in the women's health sector could accelerate the development and commercialization of new products. Acquisitions of complementary businesses could provide Evofem with access to new markets and customer segments. The timeline for strategic partnerships and acquisitions depends on the availability of suitable targets and the negotiation of mutually beneficial agreements.
• Development of New Formulations and Delivery Systems: Evofem can invest in the development of new formulations and delivery systems for its existing products and pipeline candidates. This could involve exploring new routes of administration, improving the efficacy and safety of existing products, and developing combination therapies. Innovation in formulation and delivery systems could enhance the value proposition of Evofem's products and create new market opportunities. The timeline for the development of new formulations and delivery systems depends on the complexity of the research and development process.

What Are EVFM's Competitive Advantages?

• Proprietary Products: Evofem's products, such as Phexxi, are protected by patents, providing a degree of exclusivity.
• First-Mover Advantage: Phexxi is one of the first non-hormonal contraceptive gels on the market, giving Evofem a first-mover advantage.
• Brand Recognition: Evofem is building brand recognition through its marketing efforts and partnerships with healthcare providers.

What Does EVFM Do?

Evofem Biosciences, Inc. is a biopharmaceutical company dedicated to addressing unmet needs in women's sexual and reproductive health. The company's flagship product is Phexxi, a non-hormonal vaginal gel approved for the prevention of pregnancy. Unlike traditional hormonal contraceptives, Phexxi offers women a hormone-free option. Evofem is also developing EVO100, an antimicrobial vaginal gel designed to prevent urogenital transmission of Chlamydia trachomatis and Neisseria gonorrhoeae infections. Founded with the mission of empowering women to take control of their reproductive health, Evofem has focused on developing innovative solutions that address specific concerns and preferences. The company's commercial strategy involves direct-to-consumer marketing and partnerships with healthcare providers to increase awareness and adoption of Phexxi. Evofem Biosciences, Inc. is headquartered in San Diego, California, and operates primarily in the United States. The company aims to expand its product portfolio and market reach to address a broader range of women's health issues.

What Products and Services Does EVFM Offer?

• Develop and commercialize products for women's sexual and reproductive health.
• Offer Phexxi, a non-hormonal vaginal gel for contraception.
• Develop EVO100, an antimicrobial vaginal gel for preventing urogenital infections.
• Conduct clinical trials to evaluate the safety and efficacy of its products.
• Seek regulatory approvals from the FDA and other regulatory agencies.
• Market and distribute its products through healthcare providers and direct-to-consumer channels.

How Does EVFM Make Money?

• Develops and patents proprietary pharmaceutical products.
• Generates revenue through the sale of Phexxi.
• Outsources manufacturing to contract manufacturers.
• Markets and sells products through a combination of direct-to-consumer advertising and partnerships with healthcare providers.

What Industry Does EVFM Operate In?

Evofem Biosciences, Inc. operates within the women's health segment of the biotechnology industry. The market for women's health products is substantial, driven by increasing awareness and demand for innovative solutions. The contraceptive market, in particular, is characterized by a mix of established hormonal methods and emerging non-hormonal options. Evofem's Phexxi competes with established players in the contraceptive market, offering a unique value proposition for women seeking hormone-free alternatives. The company also faces competition from other companies developing treatments for sexually transmitted infections.

Who Are EVFM's Key Customers?

• Women seeking non-hormonal contraception options.
• Healthcare providers who prescribe or recommend contraception to their patients.
• Pharmacies and distributors that stock and sell Evofem's products.

Company Profile

Evofem Biosciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Saundra Pelletier. EVFM has traded publicly since 2014.

Return on equity for Evofem Biosciences, Inc. stands at 8.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -81.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -21.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.08 means current liabilities exceed short-term assets, a liquidity point worth watching.

EVFM Valuation & Market Position

With a $1.06M market cap, Evofem Biosciences, Inc. sits in the micro-cap segment of the market.

Quarterly Financial Performance: Evofem Biosciences, Inc.

Revenue for Evofem Biosciences, Inc. came in at $2.6M during Q2 FY2026, a 192.9% improvement versus the preceding quarter. The company recorded a net loss of $11.0M, with diluted EPS of $-0.08. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, EVFM averaged $-0.03 in diluted EPS.

Evofem Biosciences, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Evofem Biosciences, Inc. has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 83.5% above estimates on average.

The most recent 10 insider filings for Evofem Biosciences, Inc. break down as 7 sales and 3 purchases. On net that is roughly 92K shares acquired (about $10K) — insiders putting money in tends to read as conviction.

EVFM Financials

EVFM Latest News

EVFM Analyst Consensus

EVFM MoonshotScore

EVFM Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources